dostęp otwarty
Tom 7, Nr 2 (2022)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2022-07-08
Pobierz cytowanie
Stanowisko Zespołu Ekspertów Polskiego Towarzystwa Ginekologów i Położników w zakresie stosowania produktu leczniczego Xonvea® do leczenia nudności i wymiotów u kobiet w ciąży
1, 2, 3, 4, 5, 6
Ginekologia i Perinatologia Praktyczna 2022;7(2):99-103.
Afiliacje- I Katedra Ginekologii i Położnictwa, Uniwersytet Medyczny w Łodzi
- Klinika Położnictwa i Perinatologii, Uniwersytet Jagielloński, Collegium Medicum w Krakowie
- I Katedra i Klinika Położnictwa i Ginekologii, Warszawski Uniwersytet Medyczny w Warszawie
- Klinika Położnictwa i Ginekologii, Pomorski Uniwersytet Medyczny w Szczecinie
- II Katedra i Klinika Ginekologii i Położnictwa, Uniwersytet Medyczny we Wrocławiu
- Klinika Perinatologii i Chorób Kobiecych, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
dostęp otwarty
Tom 7, Nr 2 (2022)
Stanowiska Ekspertów
Opublikowany online: 2022-07-08
Streszczenie
Brak
Streszczenie
Brak
Pobierz cytowanie
Informacje o artykuleTytuł
Stanowisko Zespołu Ekspertów Polskiego Towarzystwa Ginekologów i Położników w zakresie stosowania produktu leczniczego Xonvea® do leczenia nudności i wymiotów u kobiet w ciąży
Czasopismo
Ginekologia i Perinatologia Praktyczna
Numer
Typ artykułu
Wytyczne / stanowisko ekspertów
Strony
99-103
Opublikowany online
2022-07-08
Wyświetlenia strony
3047
Wyświetlenia/pobrania artykułu
2205
Rekord bibliograficzny
Ginekologia i Perinatologia Praktyczna 2022;7(2):99-103.
Autorzy
Piotr Sieroszewski
Hubert Huras
Mirosław Wielgoś
Sebastian Kwiatkowski
Mariusz Zimmer
Agnieszka Seremak-Mrozikiewicz
Referencje (30)- Matthews A, Haas DM, O’Mathúna DP, Dowswell T. Interventions for nausea and vomiting in early pregnancy. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No.: CD007575. DOI: 10.1002/14651858. CD007575.pub4. (Systematic Review).
- Attard CL, Kohli MA, Coleman S, et al. The burden of illness of severe nausea and vomiting of pregnancy in the United States. Am J Obstet Gynecol. 2002; 186(5 Suppl Understanding): S220–S227.
- Piwko C, Koren G, Babashov V, et al. Economic burden of nausea and vomiting of pregnancy in the USA. J Popul Ther Clin Pharmacol. 2013; 20: e149–160.
- O'Brien B, Naber S. Nausea and vomiting during pregnancy: effects on the quality of women's lives. Birth. 1992; 19(3): 138–143.
- Davis M. Nausea and vomiting of pregnancy: an evidence-based review. J Perinat Neonatal Nurs. 2004; 18(4): 312–328.
- Ozgoli G, Goli M, Simbar M. Effects of ginger capsules on pregnancy, nausea, and vomiting. J Altern Complement Med. 2009; 15(3): 243–246.
- Viljoen E, Visser J, Koen N, et al. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutr J. 2014; 13: 20.
- O'Donnell A, McParlin C, Robson SC, et al. Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. JAMA. 2016; 316(13): 1392–1401.
- Brent R. Medical, social, and legal implications of treating nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2002; 186(5 Suppl Understanding): S262–S266.
- Koren G, Piwko C, Ahn E, et al. Validation studies of the Pregnancy Unique-Quantification of Emesis (PUQE) scores. J Obstet Gynaecol. 2005; 25(3): 241–244.
- ACOG PRACTICE BULLETIN. Clinical Management Guidelines for Obstetrician–Gynecologists Number 189, January 2018 (Replaces Practice Bulletin 153, September 2015) Committee on Obstetric Practice — This Practice Bulletin was developed by the American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Obstetrics in collaboration with Susan M. Ramin, MD.
- Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1995; 173(3 Pt 1): 881–884.
- Persaud N, Meaney C, El-Emam K, et al. Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis. PLoS One. 2018; 13(1): e0189978.
- Koren G, Clark S, Hankins GDV, et al. Demonstration of early efficacy results of the delayed-release combination of doxylamine-pyridoxine for the treatment of nausea and vomiting of pregnancy. BMC Pregnancy Childbirth. 2016; 16(1): 371.
- Neutel CI, Johansen HL. Measuring drug effective- ness by default: the case of Bendectin. Can J Public Health. 1995; 86: 66–70.
- Koren G, Clark S, Hankins GDV, et al. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol. 2010; 203(6): 571.e1–571.e7.
- Maltepe C, Koren G. Preemptive treatment of nausea and vomiting of pregnancy: results of a randomized controlled trial. Obstet Gynecol Int. 2013; 2013: 809787.
- Kutcher JS, Engle A, Firth J, et al. Bendectin and birth defects. II: Ecological analyses. Birth Defects Res A Clin Mol Teratol. 2003; 67(2): 88–97.
- Bishai R, Mazzotta P, Atanackovic G, et al. Critical appraisal of drug therapy for nausea and vomiting of pregnancy: II. Efficacy and safety of diclectin (doxylamine-B6). Can J Clin Pharmacol. 2000; 7(3): 138–143.
- Neutel I, Johansen HI. Variation in rates hospitalization for excessive vomiting in pregnancy by Bendectin/Diclectin use in Canada. Nausea and vomiting of pregnancy. State of the art. Toronto: The Motherisk Program. 2000, 54-59.
- Atanackovic G, Navioz Y, Moretti ME, et al. The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. J Clin Pharmacol. 2001; 41(8): 842–845.
- McKeigue PM, Lamm SH, Linn S, et al. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology. 1994; 50(1): 27–37.
- Atanackovic G, Navioz Y, Moretti ME, et al. The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. J Clin Pharmacol. 2001; 41(8): 842–845.
- Nulman I, Rovet J, Barrera M, et al. Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin. J Pediatr. 2009; 155(1): 45–50, 50.e1.
- Madjunkova S, Maltepe C, Koren G. The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin ®) for the treatment of nausea and vomiting of pregnancy. Paediatr Drugs. 2014; 16(3): 199–211.
- Fejzo MS, Magtira A, Schoenberg FP, et al. Neurodevelopmental delay in children exposed in utero to hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 2015; 189: 79–84.
- Koren G, Clark S, Hankins GDV, et al. Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. BMC Pregnancy Childbirth. 2015; 15: 59.
- Nuangchamnong N, Niebyl J. Doxylamine succinate-pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview. Int J Womens Health. 2014; 6: 401–409.
- Slaughter SR, Hearns-Stokes R, van der Vlugt T, et al. FDA approval of doxylamine-pyridoxine therapy for use in pregnancy. N Engl J Med. 2014; 370(12): 1081–1083.
- Charakterystyka Produktu Leczniczego Xonvea®.
